Thank you for your interest in the role of Board Member of the Human Tissue Authority. These are important and demanding times for the health sector, for innovation in the life sciences and for issues about public trust and professional confidence. Consequently, our role as the regulator for the ethical use of human tissue has never been more vital.
We and the other regulators in the health system and the life sciences are increasingly collaborating to find ways of sharing data and our understanding of risk as well as developing shared services for support systems such as finance, IT and HR. We have co-located with many of the other regulators which is enabling us to develop our focus on joint working.
Together we are developing our ability to learn about new approaches to digitally enabled inspection and assurance as well as discussing wider developments in regulation and the life sciences and issues of joint concern about patient safety and public confidence.
Our new Board Members will have opportunities to be part of shaping the HTA’s future activities. They will also have some challenges: grasping the potential for improvement as a result of greater collaboration; the potential of even greater risk-based regulation and data-driven intelligence; increasing the diversity of our workforce; support for the life sciences; maintaining trust and confidence in our work, and responding to the increased public interest in the post-mortem sector are just a few of these challenges.
As a non-executive Board Member, you will also be able to encourage joint ways of developing the expertise and skills of our staff, inform our engagement with our varied stakeholders and reinforce our commitments to equality and inclusion.
If you have the skills and expertise to undertake the role of a Board Member and if you would enjoy the opportunity to contribute to our work at a very important time, I do hope you will consider applying for one of these important positions.
Ministers are seeking to appoint 4 new members to the Human Tissue Authority (HTA), one of which will be responsible for Chairing the HTA Audit and Risk Assurance Committee (ARAC).
Remuneration will be £7,883 per annum, with the ARAC Chair receiving £13,137 per annum, for a time commitment of 2 to 3 days per month.
As a Member of the HTA you will:
- support the Chair in setting the strategic direction of HTA, encouraging and enabling the HTA to be a first-class regulator of human tissue
- support the Chair in developing HTA in-line with the organisation’s strategic aims while maintaining a positive, constructive and appropriate relationship with its stakeholders to ensure confidence in the work of HTA
- provide an independent view, a substantive contribution, and constructive challenge at Board meetings and sub committees
- monitor the performance of HTA’s Executive, holding it to account for the delivery of HTA’s business plan, HM Treasury and Department of Health and Social Care requirements
The HTA’s key priority is to maintain public
and professional confidence in the removal, storage and use of human tissue by
ensuring that these activities are undertaken safely and ethically, and with
proper consent.
The HTA was established as an Executive
Non-Departmental Public Body on 1 April 2005 under the Human Tissue Act 2004.
It also acts as a Competent Authority in relation to EU legislation covering
tissues and cells used in patient treatment, and organ donation and
transplantation.
The HTA licences organisations that remove,
store and use human tissue and organs for purposes such as research,
transplantation, post-mortem examination, anatomical examination and public
display, as set out in its governing legislation.
The HTA publishes Codes of Practice and
Standards relating to the conduct of activities within its remit and
superintends compliance with standards through a risk-based programme of audit
and inspection. It also plays a regulatory role in living organ donation,
ensuring that valid consent is given, and no coercion or reward takes
place.
The HTA’s remit under the Human Tissue Act
extends to England, Wales, and Northern Ireland. It also carries out some
functions (in relation to EU legislation, regulating living donation, and
keeping of registers), on behalf of the Scottish Government. Since December
2015, the Human Transplantation (Wales) Act 2013 has governed consent for organ
and tissue donation in Wales, for which the HTA has produced a Code of Practice
and oversees compliance.
In addition to its roles in licensing,
inspection, and approving living organ donations, the HTA has a statutory duty
to provide advice and guidance to the public, and professionals, on activities
within its remit. It also has a duty to monitor developments and advise the
Secretary of State, and counterparts in devolved administrations, on related
issues.
As a regulator, the HTA seeks to work with
stakeholders to encourage improvement, remaining accessible and responsive to a
changing environment and the needs of the organisations it regulates. It is
regarded as being in a unique position to comment and offer guidance on
challenging issues which fall on the edge of its regulatory remit
The HTA works closely with other regulators
and industry to ensure that regulation supports innovation, whilst protecting
public confidence. In the context of Government focus on its industrial
strategy and the life sciences, HTA has identified various opportunities for
improving the current legislative framework. This will become ever more
necessary as the technology and science moves on and regulation will need to
remain apace.
The Authority’s Chair and Members are
appointed by the Secretary of State for Health and Social Care. The Chair and
half of the members are lay, with the remainder being professionals drawn from
some of the groups who are affected by the legislation.
Business Plan and Strategy: https://www.hta.gov.uk/about-hta/corporate-publications/business-plan-and-strategy
Guidance for Professionals: https://www.hta.gov.uk/guidance-professionals
Guidance for the Public: https://www.hta.gov.uk/guidance-public
Board meetings are
held 2 Redman Place, London E20 1JQ.
Upcoming meeting
dates: 6 March, 26 June, 18 September, and 4 December 2025.
This post is regulated by the Commissioner for Public Appointments. For more information, please refer to the
Commissioner’s website